206 related articles for article (PubMed ID: 27768764)
1. Combination of Cancer Stem Cell Markers CD44 and CD24 Is Superior to ALDH1 as a Prognostic Indicator in Breast Cancer Patients with Distant Metastases.
Horimoto Y; Arakawa A; Sasahara N; Tanabe M; Sai S; Himuro T; Saito M
PLoS One; 2016; 11(10):e0165253. PubMed ID: 27768764
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
7. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
9. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
[TBL] [Abstract][Full Text] [Related]
10. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
[TBL] [Abstract][Full Text] [Related]
11. Characterization of CD44+ALDH1+Ki-67- Cells in Non-malignant and Neoplastic Lesions of the Breast.
DA Cruz Paula A; Marques O; Sampaio R; Rosa A; Garcia J; Rêma A; DE Fátima Faria M; Silva P; Vizcaíno R; Lopes C
Anticancer Res; 2016 Sep; 36(9):4629-38. PubMed ID: 27630305
[TBL] [Abstract][Full Text] [Related]
12. Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.
Tsunoda Y; Sakamoto M; Sawada T; Sasaki A; Yamamoto G; Tachikawa T
Oncology; 2011; 81(5-6):336-44. PubMed ID: 22237177
[TBL] [Abstract][Full Text] [Related]
13. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469
[TBL] [Abstract][Full Text] [Related]
14. Distribution of CD44/CD24 positive cells in ductal invasive carcinoma of breast of different grade and molecular subtype.
Gudadze M; Kankava K; Mariamidze A; Mosidze T; Burkadze G
Georgian Med News; 2013 Sep; (222):50-7. PubMed ID: 24099815
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer.
Liu C; Luo Y; Liu X; Lu P; Zhao Z
Cancer Biother Radiopharm; 2012 Jun; 27(5):324-8. PubMed ID: 22702496
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
[TBL] [Abstract][Full Text] [Related]
18. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
19. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
[TBL] [Abstract][Full Text] [Related]
20. Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1-3 lymph node metastases.
Nogami T; Shien T; Tanaka T; Nishiyama K; Mizoo T; Iwamto T; Ikeda H; Taira N; Doihara H; Miyoshi S
Breast Cancer; 2014 Jan; 21(1):58-65. PubMed ID: 22407396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
